相关实验视频

Updated: Jun 10, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

甲基和JAK抑制的同时使用对心血管结果有好处吗? 一个评论评论

Peter C Taylor¹, Alejandro Balsa², Anne-Barbara Mongey³

¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. peter.taylor@kennedy.ox.ac.uk.

Rheumatology and therapy

|October 13, 2024

概括

将甲状腺素 (MTX) 与雅努斯激酶抑制剂 (JAKis) 结合使用可能为类风湿性关节炎 (RA) 患者提供心血管益处. 这种方法可以减轻与JAKis相关的心血管风险,需要进一步调查.

科学领域:

类风湿病学类风湿病学
心脏病学心脏病学
药理学药理学是指药理学的学科.

背景情况:

风湿性关节炎 (RA) 治疗指南建议用甲状腺素 (MTX) 作为一线治疗.
简氏激酶抑制剂 (JAKis) 是有效的RA治疗方法,但引起了人们对心血管 (CV) 风险的担忧.
同时服用MTX在减轻JAKi相关心脏病风险方面的作用需要评估.

研究的目的:

审查现有文献,研究在风湿性关节炎 (RA) 治疗中将甲状腺酸盐 (MTX) 与雅努斯激酶抑制剂 (JAKis) 结合使用的潜在心血管益处.
评估同时使用MTX对JAKis的心血管安全概况的影响.
探索MTX可能产生心脏保护作用的机制.

主要方法:

对临床试验和有关RA治疗结果和心血管事件的现有文献的审查.
对MTX心脏保护作用的间接证据和拟议的生物机制的分析.
考虑RA中的脂质悖论及其与各种治疗方式的相互作用.

主要成果:

临床试验证实了JAKis与MTX结合治疗RA的疗效.
目前关于主要不良心血管事件 (MACE) 的数据不足以得出关于心血管安全的最终结论.
间接证据表明,MTX可能通过降低炎症和腺积累等机制产生心脏保护作用.

结论:

同时使用MTX和JAKis可能会在RA患者中提供心血管保护.
MTX的潜在心脏保护机制包括抗炎作用和腺素通路调节.
需要进一步的研究来证实MTX和JAKis结合的CV益处,特别是考虑到RA中的脂质悖论.

关键词:

心血管疾病的心血管疾病组合疗法是一种联合疗法.雅努斯酶抑制剂的使用甲基二甲基酸盐的使用方法类风湿性关节炎类风湿性关节炎类风湿性关节炎

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

相关概念视频

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...